Pharmaceuticals

Guilin Sanjin

Guilin Sanjin released FY2025 annual earnings on April 28 (BJT), actual revenue CNY 2.046 B (forecast CNY 2.555 B), actual EPS CNY 0.74 (forecast CNY 0.89)

Guilin Sanjin released FY2025 Q4 earnings on April 28 (BJT), actual revenue CNY 583.35 M, actual EPS CNY 0.0811

Guilin Sanjin released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue CNY 525.12 M, actual EPS CNY 0.21

Guilin Sanjin FY2026 Q1 Earnings Release on April 29 After-Market (BJT)

Guilin Sanjin to Release FY2025 Earnings on April 29, 2026 (BJT), Forecast Revenue CNY 2.555 B, EPS CNY 0.89

Guilin Sanjin released FY2025 Q3 earnings on October 29 During-Market BJT, actual revenue CNY 464.04 M, actual EPS CNY 0.1695

Guilin Sanjin released FY2025 9 Months Earnings on October 29 During-Market (BJT), actual revenue CNY 1.462 B, actual EPS CNY 0.6588

Guilin Sanjin FY2025 Q3 Earnings Release on October 30 During-Market BJT

Guilin Sanjin released FY2025 Semi-Annual Earnings on August 28 After-Market (BJT), Actual Revenue CNY 998.34 M, Actual EPS CNY 0.49

Guilin Sanjin released FY2025 Q2 earnings on August 28 After-Market (BJT), actual revenue CNY 531.77 M, actual EPS CNY 0.3093

Guilin Sanjin FY2025 Semi-Annual Earnings Release on August 29, 2025 (BJT)

Guilin Sanjin Receives B Rating in Huazheng ESG Index for April 30, 2025

Zhongyou Securities Sees Growing Profitability in Guilin Sanjin

GUILIN Sanjin and ZELIN Pharmaceutical Release Research Memos: Excellent Inventory Management, New Drug Approved for Market

Guilin Jin Yin Secretary Responds to Subsidiary Operation and Funding Support

Guilin Sanjin optimizes inventory to 1.5-2 months

Subsidiary of Guilin Sanjin Receives Approval for BC006 Injection Clinical Trials

Guilin Sanjin Reports 23% Year-on-Year Growth in Net Profit for 2024

Guilin Sanjin released FY2024 Q4 earnings on April 25 After-Market BJT, actual revenue CNY 619.2 M, actual EPS CNY 0.2405

Guilin Sanjin released FY2024 Annual Earnings on April 25 After-Market (BJT), Actual Revenue: CNY 2.194 B (Forecast: CNY 2.246 B), Actual EPS: CNY 0.89 (Forecast: CNY 0.76)

002275

According to the Zhitong Finance APP, Guilin Sanjin released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 1.462 billion yuan, a year-on-year decrease of 7.14%. The net profit attributable to shareholders of the listed company was 385 million yuan, a year-on-year increase of 0.35%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 353 million yuan, a year-on-year increase of 1.70%

Zhitong

Guilin Sanjin released its performance for the first three quarters, with a net profit attributable to the parent company of 385 million yuan, a year-on-year increase of 0.35%

Guilin Sanjin announced that a board meeting will be held on October 28, 2025, to review the profit distribution plan for the first three quarters of 2025, with a planned cash distribution of 118 million yuan. This plan is based on a net profit of 385 million yuan from January to September 2025, with undistributed profits of 1.635 billion yuan. A cash distribution of 2 yuan will be made for every 10 shares, with no bonus shares or capital increase

Guilin Sanjin plans to distribute 118 million yuan in cash in the first three quarters of 2025

Guilin Sanjin Pharmaceutical provided a guarantee of 20 million yuan to Baochuan Biotechnology, a wholly-owned subsidiary, to Xiamen International Bank Shanghai Branch, with a guarantee period from August 12, 2025, to August 12, 2028. This guarantee is within the approved guarantee limit of 270 million yuan by the company. After the guarantee, Baochuan Biotechnology's guarantee balance increased to 95.7 million yuan, with a remaining available limit of 20 million yuan

Guilin Sanjin provides an additional guarantee of 20 million yuan for its subsidiary Baochuan Biotechnology

300158

002287

600594

300436

002644

A-share pharmaceutical stocks continue to adjust, CheezhengTTM approaches the limit down, and multiple stocks such as Xintian Pharmaceutical, Hanyu Pharmaceutical, Guilin Sanjin, Foci Pharmaceutical, YIBAI PHARMACEUTICAL, Zhendong Pharmacy, and Cosunter have fallen over 5%

Wallstreetcn

Zhendong Pharmacy

CheezhengTTM

YIBAI PHARMACEUTICAL

Cosunter

Foci Pharmaceutical

300199

001367

002728

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin dropping over 6%, and HYBIO, Cosunter, Haisen Pharm, TY PHAR., and others following suit

HYBIO

Haisen Pharm

TY PHAR.

The generic drug consistency evaluation sector has declined in the short term, with Guilin Sanjin falling over 6%

As global markets face trade policy complexities and inflation trends, dividend stocks remain appealing for steady income. The top 10 global dividend stocks include en-japan, Daito Trust Construction, Allianz, and others, with yields ranging from 4.04% to 4.93%. Companies like ORION Holdings and Guilin Sanjin Pharmaceutical show strong dividend coverage but have faced volatility. Qingdao Baheal Medical, despite recent earnings pressure, maintains sustainable dividends. This analysis highlights the importance of dividend stocks in a fluctuating market, providing insights for investors seeking reliable returns.

Simplywall

Orion

Essential Properties Realty

Global Dividend Stocks To Consider In June 2025

According to the Zhitong Finance APP, Guilin Sanjin announced that its holding subsidiary, Baochuan Biopharmaceutical Technology (Shanghai) Co., Ltd. (referred to as "Baochuan Biopharma"), has received the clinical trial approval for BC006 monoclonal antibody injection issued by the National Medical Products Administration, allowing the commencement of clinical trials for the indication of idiopathic pulmonary fibrosis

Guilin Sanjin: BC006 monoclonal antibody injection new indication approved for clinical trials

Guilin Sanjin(002275.SZ)